Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome

Last reviewed

🖨 Print for my doctorAdvocacy Hub →
ORPHA:2250OMIM:603457Q87.0
Who is this for?
Show terms as
8Treatment centers

Where are you in your journey?

UniteRare data is sourced from FDA.gov, ClinicalTrials.gov, Orphanet, OMIM, and NORD.
Report missing data

Overview

Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome, also known as Bosma arhinia microphthalmia syndrome (BAMS), is an extremely rare congenital condition characterized by the triad of complete absence of the nose (arhinia) or severe nasal hypoplasia, ocular defects (microphthalmia or anophthalmia), and hypogonadotropic hypogonadism. The condition is present from birth and affects multiple body systems including the craniofacial structures, the eyes, the olfactory system, and the reproductive endocrine axis. Patients typically have absent or severely underdeveloped external nasal structures, absent or rudimentary nasal passages, and absent paranasal sinuses. The olfactory system is affected, leading to hyposmia (reduced sense of smell) or anosmia (complete absence of smell). Eye abnormalities range from small eyes (microphthalmia) to absent eyes (anophthalmia), with variable degrees of visual impairment. Hypogonadotropic hypogonadism results from deficient gonadotropin-releasing hormone signaling, leading to delayed or absent puberty and potential infertility. The genetic basis of BAMS has been linked to mutations in the SMCHD1 gene, which plays a role in epigenetic regulation and chromatin organization. The condition appears to arise from de novo dominant mutations in most reported cases. Management is multidisciplinary and symptomatic, involving reconstructive craniofacial surgery to address nasal defects, ophthalmologic care for ocular abnormalities (including prosthetic eyes when needed), airway management, and hormone replacement therapy to induce puberty and address hypogonadism. Fertility treatment may be considered in adulthood. Due to the extreme rarity of this condition, with fewer than 50 cases reported in the medical literature, management is guided primarily by case reports and expert opinion rather than clinical trials.

Also known as:

Clinical phenotype terms— hover any for plain English:

Tooth malpositionHP:0000692External genital hypoplasiaHP:0003241HyposmiaHP:0004409Failure of eruption of permanent teethHP:0006352Aplasia of the noseHP:0009927Single narisHP:0009932Hypoplasia of the olfactory bulbHP:0040326Absent naresHP:0100596AnophthalmiaHP:0000528
Inheritance

Autosomal dominant

Passed on from just one parent; each child has about a 50% chance of inheriting it

Age of Onset

Neonatal

Begins at or shortly after birth (first 4 weeks)

Orphanet ↗OMIM ↗NORD ↗

Treatments

No FDA-approved treatments are currently listed for Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.

View clinical trials →

No actively recruiting trials found for Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome at this time.

New trials open frequently. Follow this disease to get notified.

Search ClinicalTrials.gov ↗Join the Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome community →

No specialists are currently listed for Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.

View NORD Rare Disease Centers ↗Undiagnosed Disease Network ↗

Treatment Centers

8 centers
🏥 NORD

Baylor College of Medicine Rare Disease Center

Baylor College of Medicine

📍 Houston, TX

🏥 NORD

Stanford Medicine Rare Disease Center

Stanford Medicine

📍 Stanford, CA

🔬 UDN

NIH Clinical Center Undiagnosed Diseases Program

National Institutes of Health

📍 Bethesda, MD

🔬 UDN

UCLA UDN Clinical Site

UCLA Health

📍 Los Angeles, CA

🔬 UDN

Baylor College of Medicine UDN Clinical Site

Baylor College of Medicine

📍 Houston, TX

🔬 UDN

Harvard/MGH UDN Clinical Site

Massachusetts General Hospital

📍 Boston, MA

🏥 NORD

Mayo Clinic Center for Individualized Medicine

Mayo Clinic

📍 Rochester, MN

👤 Mayo Clinic Center for Individualized Medicine

🏥 NORD

UCLA Rare Disease Day Program

UCLA Health

📍 Los Angeles, CA

Travel Grants

No travel grants are currently matched to Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.

Search all travel grants →NORD Financial Assistance ↗

Community

Open Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndromeForum →

No community posts yet. Be the first to share your experience with Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.

Start the conversation →

Latest news about Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome

No recent news articles for Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome.

Follow this condition to be notified when news becomes available.

Caregiver Resources

NORD Caregiver Resources

Support, advocacy, and financial assistance for caregivers of rare disease patients.

Mental Health Support

Rare disease caregiving can be isolating. Connect with counseling and peer support.

Family & Caregiver Grants

Financial assistance programs specifically for caregivers of rare disease patients.

Social Security Disability

Learn how rare disease patients may qualify for SSDI/SSI benefits.

Common questions about Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome

What is Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome?

Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome, also known as Bosma arhinia microphthalmia syndrome (BAMS), is an extremely rare congenital condition characterized by the triad of complete absence of the nose (arhinia) or severe nasal hypoplasia, ocular defects (microphthalmia or anophthalmia), and hypogonadotropic hypogonadism. The condition is present from birth and affects multiple body systems including the craniofacial structures, the eyes, the olfactory system, and the reproductive endocrine axis. Patients typically have absent or severely underdeveloped exte

How is Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome inherited?

Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome follows a autosomal dominant inheritance pattern. Genetic counseling can help families understand recurrence risk and testing options.

At what age does Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome typically begin?

Typical onset of Hyposmia-nasal and ocular hypoplasia-hypogonadotropic hypogonadism syndrome is neonatal. Age of onset can vary across affected individuals.